Tricaprilin

Summary

Tricaprilin (CHEMBL1406148) is a phase-3 clinical-stage small-molecule anticonvulsant; indicated across 7 conditions including alzheimer disease and migraine disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 7 conditions
• Clinical trials: 21
• Chemistry: 470.7 Da · C27H50O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1406148
Name	Tricaprilin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10850
ChEBI	CHEBI:76978
Molecular formula	C27H50O6
Molecular weight	470.7
InChIKey	VLPFTAMPNXLGLX-UHFFFAOYSA-N

SMILES: CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC

IUPAC name: 2,3-di(octanoyloxy)propyl octanoate

ChEBI definition: A triglyceride obtained by acylation of the three hydroxy groups of glycerol by octanoic acid. Used as an alternative energy source to glucose for patients with mild to moderate Alzheimer’s disease.

Pharmacological roles (ChEBI): anticonvulsant.

Other ChEBI roles (chemical / environmental): plant metabolite.

Also known as: AC-1202, AC-1204, Axona, Caprylic acid triglyceride, Caprylic triglyceride, CER-0001, Glyceryl tricaprylate, Miglyol 808, NSC-4059, Tricaprilin, Tricaprilina, Tricapriline

Patent coverage: 5,093 distinct patent families (12,561 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prelamin-A/C, Aldehyde dehydrogenase 1A1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	7.75	Potency	17.8	nM	CHEMBL_ACT_3652747

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	3	MONDO:0004975	MONDO:0004975
migraine disorder	2	MONDO:0005277	MONDO:0005277
chronic progressive multiple sclerosis	2	MONDO:0005284	EFO:0003840
relapsing-remitting multiple sclerosis	2	MONDO:0005314	EFO:0003929
amyotrophic lateral sclerosis	1	MONDO:0004976	MONDO:0004976

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 21.

Phase distribution

Phase	Trials
PHASE1	10
Not specified	4
PHASE2	3
PHASE2/PHASE3	2
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05809908	PHASE3	NOT_YET_RECRUITING	Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
NCT01211782	PHASE2/PHASE3	WITHDRAWN	AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
NCT01741194	PHASE2/PHASE3	COMPLETED	AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
NCT04187547	PHASE3	WITHDRAWN	A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer’s Disease With Optional Open Label Extension
NCT00142805	PHASE2	COMPLETED	Tricaprilin in Mild to Moderate Alzheimer’s Disease
NCT00355550	PHASE2	COMPLETED	Tricaprilin In Age-Associated Memory Impairment
NCT04437199	PHASE2	COMPLETED	Tricaprilin Phase 2 Pilot Study in Migraine
NCT02747602	PHASE1	COMPLETED	Evaluation of PK of AC1204 v Caprylic Triglyceride Oil Incl Food Effect on Ketone Body Production
NCT02833012	PHASE1	COMPLETED	Evaluation of PK of Caprylic Triglyceride Oil, AC-1202, AC-1204, and Axona on Ketone Body Production
NCT03063645	PHASE1	COMPLETED	Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production
NCT03551769	PHASE1	COMPLETED	Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production
NCT03628352	PHASE1	COMPLETED	Taste-masking Study for Tricaprilin in Sensory Panelists
NCT03635879	PHASE1	WITHDRAWN	Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides
NCT03971123	PHASE1	COMPLETED	Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production
NCT04268953	PHASE1	COMPLETED	Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production
NCT04727970	PHASE1	COMPLETED	Tricaprilin Infantile Spasms Pilot Study
NCT05028114	PHASE1	TERMINATED	Tricaprilin Liquid Formulation PK Study
NCT01848327	Not specified	COMPLETED	Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis
NCT02679222	Not specified	COMPLETED	Comparing the Ketogenic Effect of Coconut Oil and Different MCTs
NCT02716662	Not specified	COMPLETED	Safety of Caprylic Triglycerides in ALS: A Pilot Study
NCT03223389	Not specified	UNKNOWN	Fat Metabolites and Gut Hormones

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).